



**DECISION DIAGNOSTICS CORP.**

**OTC PINK**

**ANNUAL REPORT 2013 – 2014**

**SUPPLEMENTAL DISCLOSURE STATEMENT**

# Decision Diagnostics Corp.

## OTC Pink Basic Disclosure Guidelines

### 1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

DECISION DIAGNOSTICS CORP. (11/25/2011-present)  
INSTACARE CORP. (through 11/25/2011)

### 2) Address of the issuer's principal executive offices

Company Headquarters  
Address 1: 2660 TOWNSGATE ROAD  
Address 2: SUITE 300  
Address 3: WESTLAKE VILLAGE, CA 91361  
Phone: 805-446-1973  
Email: info@decisiondiagnostics.com  
Website(s): www.decisiondiagnostics.com

IR Contact N/A

### 3) Security Information

Trading Symbol: DECN  
Exact title and class of securities outstanding: COMMON  
CUSIP: **243443 108**  
Par or Stated Value: \$0.001  
Total shares authorized: 494,995,000 as of: 12/31/2014  
Total shares outstanding: 43,948,741 as of: 12/31/2014

Additional class of securities (if necessary):

Trading Symbol: N/A  
Exact title and class of securities outstanding: PREFERRED  
CUSIP: N/A  
Par or Stated Value: \$0.001  
Total shares authorized: 3,738,500 as of: 12/31/2014  
Total shares outstanding: NONE as of: 12/31/2014

Additional class of securities (if necessary):

Trading Symbol: N/A  
Exact title and class of securities outstanding: PREFERRED SERIES "B"  
CUSIP: N/A  
Par or Stated Value: \$0.001  
Total shares authorized: 2,500 as of: 12/31/2014  
Total shares outstanding: 1,000 as of: 12/31/2014

Additional class of securities (if necessary):  
Trading Symbol: N/A  
Exact title and class of securities outstanding: PREFERRED SERIES "C"  
CUSIP: N/A  
Par or Stated Value: \$0.001  
Total shares authorized: 10,000 as of: 12/31/2014  
Total shares outstanding: 2,610 as of: 12/31/2014

Additional class of securities (if necessary):  
Trading Symbol: N/A  
Exact title and class of securities outstanding: PREFERRED SERIES "D"  
CUSIP: N/A  
Par or Stated Value: \$0.001  
Total shares authorized: 500 as of: 12/31/2014  
Total shares outstanding: NONE as of: 12/31/2014

Additional class of securities (if necessary):  
Trading Symbol: N/A  
Exact title and class of securities outstanding: PREFERRED SERIES "E"  
CUSIP: N/A  
Par or Stated Value: \$0.001  
Total shares authorized: 1,250,000 as of: 12/31/2014  
Total shares outstanding: 750,400\* as of: 12/31/2014

(\*) includes Preferred E shares held in joint Escrow established for future issuances according to the agreement between the parties dated December 13, 2013.

Transfer Agent

Name: ACTION STOCK TRANSFER CORP.

Address 1: 2469 E. FORT UNION BLVD.

Address 2: SUITE 214

Address 3: SALT LAKE CITY, UT 84121

Phone: 801-274-1088

Is the Transfer Agent registered under the Exchange Act?\* Yes:  No:

\*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

List any restrictions on the transfer of security:

None

Describe any trading suspension orders issued by the SEC in the past 12 months.

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

1:14 reverse stock split of \$0.001 par value common stock effective 11/25/2011

#### **4) Issuance History**

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities

issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:

12/1/2011	1 for 14 Reverse Split	8,461,032	8,461,032
12/19/2011	New Issuance-Kimberly Binder	75	8,461,107
12/19/2011	New Issuance-Patrick DiParini	200	8,461,307
12/30/2011	10% Stock Dividend	846,669	9,307,976
1/3/2012	DTC Rounding shares	(42)	9,307,934
1/4/2012	New Issuance-Positive Revolution Inc-S-8	100,000	9,407,934
1/11/2012	Converted to Common-Alpha Credit	294,000	9,701,934
1/18/2012	New Issuance-Debt Conv. Andrew Edenbaum	53,354	9,755,288
1/23/2012	DTC Rounding shares	25	9,755,313
3/5/2012	New Issuance-JFS Investments Inc	60,000	9,815,313
3/5/2012	New Issuance-Garden State Securities	60,000	9,875,313
3/5/2012	New Issuance-Excell Advisors	30,000	9,905,313
3/5/2012	Return to Treasury-Positive Revolution	(100,000)	9,805,313
3/5/2012	New Issuance-TPC Holdings Group-ESOP-06	300,000	10,105,313
3/5/2012	New Issuance-Cadence Consulting-ESOP-06	50,000	10,155,313
3/30/2012	New Issuance-Alpha Credit Resources	238	10,155,551
6/27/2012	New Issuance-Rocio C Carazas-ESOP-06	375,000	10,530,551
6/27/2012	New Issuance-Marjolein Imfeld-ESOP-06	375,000	10,905,551
9/26/2012	Converted to Common-Centurion	172,200	11,077,751
10/9/2012	New Issuance-Aubyn Inc-ESOP-06	400,000	11,477,751
11/8/2012	Return to Treasury-Aubyn Inc-ESOP-06	(200,000)	11,277,751
11/8/2012	New Issuance-Mayer & Assoc. Esop-04	650,000	11,927,751
11/8/2012	New Issuance-Mayer & Associates	200,000	12,127,751
11/8/2012	New Issuance-Curing Capital Inc	400,000	12,527,751
11/13/2012	Converted to Common-Centurion	182,000	12,709,751
11/13/2012	New Issuance-Econ Corporate Services	50,000	12,759,751
11/13/2012	New Issuance-Call Van Zant-ESOP-06	100,000	12,859,751
11/13/2012	New Issuance-Darren Bankstead-ESOP-06	50,000	12,909,751
11/13/2012	New Issuance-Axiom Financial Inc	200,000	13,109,751
12/21/2012	Cancellation-Mayer & Associates LLC	(200,000)	12,909,751
12/21/2012	New Issuance-Mayer & Associates LLC	1,000,000	13,909,751
1/7/2013	New Issuance-Mayer & Associates LLC	50,000	13,959,751
1/7/2013	Converted to Common-Apex Clearing	210,000	14,169,751
1/7/2013	Converted to Common-Apex Clearing	236,600	14,406,351
2/15/2013	New Issuance-TPC Holdings Group-ESOP	1,325,000	15,731,351
2/15/2013	New Issuance-Envisionte LLC-ESOP	700,000	16,431,351
2/15/2013	New Issuance-Bridgeview Capital Group ESOP	700,000	17,131,351
2/15/2013	New Issuance-Cadence Holdings LLC ESOP	275,000	17,406,351
2/15/2013	New Issuance-AAC Group LLC ESOP	600,000	18,006,351
2/15/2013	New Issuance-Cadence Holdings LLC ESOP	150,000	18,156,351
2/15/2013	New Issuance-St Andrews Inc	1,000,000	19,156,351
2/15/2013	New Issuance-Alan Binder ESOP	100,000	19,256,351
2/15/2013	New Issuance-Dale Richter ESOP	100,000	19,356,351
2/15/2013	New Issuance-Kimberly Binder ESOP	50,000	19,406,351
2/15/2013	New Issuance-Maria Luz Johnson-ESOP	25,000	19,431,351
2/18/2013	Converted to Common-Apex Clearing	324,800	19,756,151
2/22/2013	New Issuance-Robert Herskowitz ESOP	500,000	20,256,151
2/22/2013	New Issuance-Jeff Whitelaw	125,000	20,381,151
2/22/2013	New Issuance-Brent England	75,000	20,456,151

5/9/2013	Converted to Common-Apex Clearing	868,000	21,324,151
5/10/2013	Cancellation-Robert Herskowitz ESOP	(500,000)	20,824,151
5/10/2013	Cancellation-St. Andrews	(1,000,000)	19,824,151
5/10/2013	New Issuance-Chase Financing Inc ESOP	350,000	20,174,151
5/10/2013	New Issuance-Mayer & Associates LLC ESOP	1,000,000	21,174,151
8/7/2013	New Issuance-St Andrews Inc ESOP	500,000	21,674,151
8/15/2013	New Issuance-Robert Herskowitz ESOP	25,000	21,699,151
8/27/2013	Cancellation-Curring Capital	(200,000)	21,499,151
8/27/2013	Cancellation-ACC Group ESOP	(600,000)	20,899,151
8/27/2013	New Issuance-Benjamin Mayer ESOP	950,000	21,849,151
9/20/2013	New Issuance-SLCC Partners LLC	1,000,000	22,849,151
9/20/2013	New Issuance-Envisionte LLC-ESOP	500,000	23,349,151
9/20/2013	New Issuance-Thomas Hanson-ESOP	250,000	23,599,151
9/20/2013	New Issuance-Envisionte LLC-ESOP	250,000	23,849,151
10/2/2013	New Issuance-Joanne Broeders-ESOP	235,300	24,084,451
10/2/2013	Cancellation-Alan Binder ESOP	(100,000)	23,984,451
10/2/2013	New Issuance-Kimberly Binder	100,000	24,084,451
10/2/2013	Converted to Common-COR Clearing	1,078,000	25,162,451
10/28/2013	Converted to Common-Michael Belcher	350,000	25,512,451
10/28/2013	New Issuance	2,798,728	28,311,179
10/30/2013	New Issuance-Benjamin Mayer ESOP	100,000	28,411,179
10/30/2013	New Issuance-Benjamin Mayer	300,000	28,711,179
10/30/2013	New Issuance	166,365	28,877,544
11/11/2013	Conversion-Centurion Credit	980,000	29,857,544
11/11/2013	New Issuance-Benjamin Mayer ESOP	500,000	30,357,544
11/11/2013	New Issuance	125,000	30,482,544
12/4/2013	Conversion-Centurion Credit	1,220,800	31,703,344
12/23/2013	New Issuance-Mark Herskowitz ESOP	175,000	31,878,344
12/23/2013	New Issuance-Benjamin Mayer ESOP	600,000	32,478,344
12/23/2013	New Issuance	1,200,548	33,678,892
1/2/2014	New Issuance	2,709,678	36,388,570
1/15/2014	New Issuance	748,720	37,137,290
1/15/2014	New Issuance	267,105	37,404,395
2/18/2014	Conversion-Alpha Credit	611,940	38,016,335
2/18/2014	Conversion-Michael Belcher	350,000	38,366,335
2/19/2014	Conversion-Mayer & Associates	798,000	39,164,335
3/28/2014	Conversion-Alpha Credit	523,740	39,688,075
3/28/2014	New Issuance	400,000	40,088,075
6/3/2014	Conversion-Alpha Credit	499,996	40,588,071
6/4/2014	Conversion-Mayer & Associates	1,115,660	41,703,731
8/14/2014	Conversion-Alpha Credit	245,000	41,948,731
8/15/2014	Conversion-Mayer & Associates	550,000	42,498,731
9/9/2014	Conversion-Mayer & Associates	775,000	43,273,731
10/28/2014	Conversion	675,010	43,948,741
1/21/2015	New Issuance	1,875,000	45,823,741
1/28/2015	New Issuance	850,000	46,673,741
2/23/2015	Conversion-Alpha Credit	705,124	47,378,865

#### PREFERRED B STOCK

Date	Description	Change in Shares	Running Total
3/23/2011	New Issuance-Centurion Credit Resources	1,000	1,000

PREFERRED C STOCK

Date	Description	Change in Shares	Running Total
1/4/2012	New Issuance-Michael Belcher	1,250	1,250
8/27/2013	New Issuance-Lathrop Gage LLC	1,500	2,750
10/28/2013	Conversion-Michael Belcher	(70)	2,680
2/18/2014	Conversion-Michael Belcher	(70)	2,610

PREFERRED E STOCK

Date	Description	Change in Shares	Running Total
8/1/2008	New Issuance-Centurion Credit	14,900	14,900
11/5/2008	New Issuance-Centurion Credit	21,225	36,125
12/16/2008	New Issuance-Centurion Credit	30,785	66,910
1/15/2009	New Issuance-Centurion Credit	40,000	106,910
3/31/2009	New Issuance-Centurion Credit	23,000	129,910
3/31/2009	New Issuance-Centurion Credit	19,000	148,910
4/1/2009	Converted to Common	(14,900)	134,010
5/13/2009	New Issuance-Centurion Credit	17,800	151,810
6/2/2009	New Issuance-Centurion Credit	25,000	176,810
7/8/2009	New Issuance-Centurion Credit	25,000	201,810
8/13/2009	New Issuance-Centurion Credit	13,000	214,810
9/11/2009	New Issuance-Centurion Credit	12,600	227,410
10/7/2009	New Issuance-Centurion Credit	20,000	247,410
11/4/2009	New Issuance-Centurion Credit	16,700	264,110
11/18/2009	New Issuance-Centurion Credit	60,000	324,110
11/20/2009	Converted to Common	(92,010)	232,100
11/23/2009	Converted to Common	(59,800)	172,300
12/7/2009	Converted to Common	(25,000)	147,300
12/8/2009	New Issuance-Centurion Credit	720,000	867,300
1/20/2010	Converted to Common	(25,000)	842,300
2/16/2010	Converted to Common	(13,000)	829,300
3/17/2010	Converted to Common	(12,600)	816,700
4/16/2010	Converted to Common	(20,000)	796,700
5/25/2010	Converted to Common	(16,700)	780,000
6/4/2010	Converted to Common	(60,000)	720,000
7/19/2010	Converted to Common	(10,000)	710,000
8/4/2010	New Issuance-Centurion Credit	200,000	910,000
1/26/2011	Converted to Common	(54,500)	855,500
3/8/2011	New Issuance-Centurion Credit	240,000	1,095,500
5/17/2011	Converted to Common	(135,200)	960,300
5/17/2011	New Issuance-Centurion Credit	135,000	1,095,300
1/11/2012	Converted to Common	(21,000)	1,074,300
3/30/2012	New Issuance-Alpha Credit Resources	124,700	1,199,000
9/26/2012	Converted to Common	(12,300)	1,186,700
11/13/2012	Converted to Common	(13,000)	1,173,700
1/7/2013	Converted to Common	(15,000)	1,158,700
1/7/2013	Converted to Common	(16,900)	1,141,800
2/18/2013	Converted to Common	(23,200)	1,118,600
5/9/2013	Converted to Common	(62,000)	1,056,600

10/2/2013	Converted to Common	(77,000)	979,600
11/11/2013	Conversion-Centurion Credit	(70,000)	909,600
12/4/2013	Conversion-Centurion Credit	(87,200)	822,400
1/15/2014	Conversion-Alpha Credit	(53,480)	768,920
2/18/2014	New Issuance-Mayer & Associates	125,000	893,920
2/18/2014	Conversion-Alpha Credit	(43,710)	850,210
2/19/2014	Conversion-Mayer & Associates	(57,000)	793,210
3/28/2014	Conversion-Alpha Credit	(37,400)	755,810
6/3/2014	Conversion-Alpha Credit	(35,714)	720,096
6/4/2014	Conversion-Mayer & Associates	(79,690)	640,406
8/14/2014	Conversion-Alpha Credit	(17,500)	622,906
8/15/2014	Conversion-Mayer & Associates	(39,285)	583,621
9/9/2014	Conversion-Mayer & Associates	(55,357)	528,264
10/28/2014	Conversion-Mayer & Associates	(30,358)	497,906
1/21/2015	New Issuance-Robert Herskowitz	100,000	597,906
1/21/2015	New Issuance-Mayer & Associates	135,000	732,906
1/21/2015	New Issuance-Alpha Credit Resources	67,860	800,766
2/23/2015	New Issuance-Alpha Credit Resources	(50,366)	750,400

- A. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

See above

## 5) Financial Statements

### **SEE FINANCIAL STATEMENTS ATTACHED TO THIS DISCLOSURE STATEMENT**

## 6) Describe the Issuer's Business, Products and Services

Decision Diagnostics Corp. (formerly instaCare Corp) is a manufacturer of the GenStrip 50 ("GenStrip"), a proprietary diabetes glucose monitoring device (strip), and just recently with the release of a design concept, we became the concept designers and manufacturers for a wireless, cloud and satellite enabled diagnostic product system now in the advanced stages of development. We are also a nationwide non-prescription diagnostics and at-home testing products distributor. Diagnostic test kits and at-home patient testing products, GenStrip is a Class II device, are regulated by the U.S. FDA in a manner similar to prescription drugs, requiring pre-market approval, but the products we distribute, for the most part, do not require, for patient use, a doctor's prescription for anything other than insurance benefit compliance. The process to receive a doctor's order is not an onerous process, and presently over 12 million patients have received these orders at one time or another. Another 8 million Americans use glucose test strips purchased without having or using health insurance.

Our subsidiaries, Pharma Tech Solutions, Inc., Pharmtech Direct Corp. and PDA Services, Inc. operate in several healthcare products distribution channels. Until October 1, 2013 we distributed brand name prescription and non-prescription diagnostics products, as well as several lines of ostomy, wound care and post-surgery medical products. However, with the FDA clearance on November 2012 (k103542) of the proprietary GenStrip we began the process of gearing up to introduce this product to several market channels. The launch of the GenStrip occurred in March 2013, however, our launch has occurred in fits and starts due to several complex legal issues involving a subsidiary of the Johnson & Johnson company. We prevailed in a major legal ruling in November 2013, and subsequent to that court ruling we have marketed Genstrip on a nationwide basis. Although there are competing estimates for the size of the market that GenStrip competes, one enduring 3<sup>rd</sup> party forecast estimates the diabetes testing market to be an estimated \$22.5 billion worldwide market.

Genstrip was the first alternative glucose testing strip that has been launched in this decade and was the first sold into the market since early 2008. Genstrip competes with a decade old but ubiquitous predicate product currently used daily by over 3 million

diabetes afflicted Americans, and an estimated 2 million diabetes afflicted people outside of the United States. However, the two largest markets for Genstrip are retail markets where uninsured and under-insured Americans shop for value and discount and in direct to patient markets which have changed dramatically in the past six months due to the federal cost cutting brought about by the 2013 “Sequester” and the deep Medicare cost cuts that took effect on July 1, 2013, brought on by the Affordable Care Act.. Federal reimbursement for direct to patient providers was lowered by 68% on July 1, 2013, making Genstrip an economical and needed solution for those estimated 5.8 million diabetics that have used and are using the predicate product but can no longer afford the predicate product test strips.

Our company, originally a medical IT company with proprietary IT product lines, acquired its medical products distribution business in late 2004 through a merger with Phoenix, Arizona based CareGeneration, Inc. Decision Diagnostics has spent the last 10 years building this business. The introduction of GenStrip was our first vertical integration into this market. We have grown the original CareGeneration business through subsequent acquisitions of small private technology businesses and strategic partnerships with larger private pharmacies. In November and December 2011 we acquired two small private concerns, both acquisitions intended to assist our launch of Genstrip, and to ease the patient service commitment that Genstrip now requires. With the launch of our new proprietary diagnostic system product, we are evaluating a third small private acquisition. We have recently implemented a full quality system for GenStrip along with our contract manufacturer partner. Our Pharma Tech subsidiary has added space in York, PA for these quality manufacturing purposes.

On March 20, 2014 our subsidiary Pharma Tech Solutions, Inc. (Pharma Tech) acquired the 510k (FDA clearance), the Marks and private registrations of Shasta Technologies LLC, which included with this asset and property purchase also required a change in the company’s registration with the U.S. FDA whereby Pharma Tech is now the registrant owner/operator and is fully responsible for the regulatory, manufacturing and distribution aspects of the product under its own umbrella. The major benefit of this acquisition is that Pharma Tech has lowered its cost of goods by 40% in an extremely cost conscious market environment. In addition, Shasta Technologies LLC had proven ineffective in managing the required responsibilities of the regulatory management of a Class II medical device, and was cited by the FDA for these deficiencies after our transaction.

We have been in litigation with Lifescan Inc. a subsidiary of Johnson & Johnson since September 2011. Lifescan has maintained throughout that we infringe on three of their patents. One of these patents has become the subject of peripheral litigation activities, two Appeals (one for each side) to the U.S. Appeals Court for the Federal Circuit (the patents appeals court). Throughout the company has prevailed. Recently, the office of the Solicitor General has intervened against Lifescan Inc. Final rulings are expected in 2015.

We intend to acquire additional private companies in this industry to achieve our goal of becoming a full service, vertically integrated, value added provider of products and services to an ever-growing market. In December 2014 we began discussions with several Asian contract manufacturers regarding the adding of manufacturing capabilities. Subsequently we have narrowed our search to three Korean concerns.

Decision Diagnostics, through its PDA Services, Inc. and Decision IT Corp. subsidiaries, also offers information technology solutions in several medical care market channels by providing physicians with information at the point of care. Our products, unlike those from many other medical information companies, make use of smart cell phones such as the Apple iPhone, the Palm Pre, the Google Droid and a wide selection of Microsoft Windows based smart phones and operate in either in a wireless or “wired” mode, which allow physicians to carry, access and update their patients’ histories, also known as electronic medical records or EMR/EHR, medication data, and best care guidelines - *all at the point of care*, or from any other location the physician may be located. In addition, the company’s products employ proprietary mathematical game theory features adapted by the company for medical use that allow acceptance of diagnoses and treatment protocols where the medical information may have originated from one or several locations and one time or several times.

A. Date and State (or Jurisdiction) of Incorporation:

INCORPORATED IN THE STATE OF NEVADA ON MARCH 2, 2001 AS ATR SEARCH CORPORATION

B. the issuer’s primary and secondary SIC Codes;

5122, 7371

C. the issuer’s fiscal year end date;



## DECEMBER 31

D. principal products or services, and their markets;

Genstrip 50 Glucose Test Strips for use with Johnson & Johnson Lifescan glucometers. MD@Hand medical communication and EMR software for use with smart cell phones.

### 7) Describe the Issuer's Facilities

We currently maintain an executive office at 2660 Townsgate Road, Suite 300, Westlake Village, CA 91361. The space consists of approximately 2,300 square feet. The monthly rental for the space is \$2,170 per month on a month-to-month basis. Our Pharma Tech subsidiary maintains its primary operations facility for quality control and FDA QSR at 735 Borom Road, York, PA

### 8) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

Our executive officers, directors, and key employees are:

<u>Name</u>	<u>Age</u>	<u>Position</u>
Keith Berman	61	Chief Financial Officer and Director
William Lyons	61	Director
Robert Jagunich	66	Director

Our shareholders elect our directors annually and our board of directors appoints our officers annually. As of the date of this filing, we have not held an annual meeting. All current directors have been held over until such time the annual meeting is held. Vacancies in our board are filled by the board itself. Set forth below are brief descriptions of the recent employment and business experience of our executive officers and directors.

**Keith Berman** has served as President, Chief Financial Officer, Secretary, Treasurer and Director of the Company since January of 2003. For over the past 25 years, Mr. Berman has been involved in the development of healthcare software including Intranet and Internet systems, and the development of novel medical diagnostics and medical devices. From July 1999 to present, Mr. Berman has held the position of President, founder and director of Caredecision.net, Inc. a private company engaged in e-health technology development. From March 2001 through June 2002 Mr. Berman also held the Position of President and Director of Medicius, Inc. From January 1996 to June 1999 Mr. Berman was the President and founder of Cymedix, the operating division of Medix Resources, Inc., now Ramp Corp. (RCO). Cymedix was a pioneer company in what was then known as i-health (Internet healthcare) now the e-health industry. Mr. Berman's professional background provides the Company with business management experience and an in depth knowledge of our industry. Mr. Berman received a BA in 1975 and an MBA in 1977, from Indiana University.

**Robert Jagunich** has served as a Director of the Company since January of 2003. Mr. Jagunich has 32 years of experience in the medical systems and device industry. From August 1992 to present, he has held the position of President at New Abilities Systems, a privately held manufacturer of advanced electronic systems used in rehabilitation. He also provides consulting services to companies such as Johnson and Johnson and has served as a senior executive in such publicly held companies as Laserscope and Acuson. From April 1996 to December 1997 Mr. Jagunich acted as a director of Cymedix Corporation, the operating entity of Medix Resources, Inc., and later, Ramp Corp. (formerly AMEX:RCO). Mr. Jagunich's professional focus on medical devices as well as the professional

relationships he has developed throughout his career provides the Company with opportunities to expand current markets and utilize additional product resources not previously available. He received his BS in 1969, and his MS and MBA in 1971, from the University of Michigan.

**William Lyons** has served as a Director of the company from January 2003 through October 2003 and most recently from January 2010 to the present time. Mr. Lyons is currently President and COO of Beacon Medical, Inc. a company specializing in the development, manufacturing, marketing and distribution of medical devices and instruments targeted primarily to the Plastic Surgery medical specialty. Prior to that, Mr. Lyons was co-founder, Executive Vice President and Director of BioElectronics Corporation. Mr. Lyons has successfully performed as President or Executive Vice President of several healthcare start-up communication technology and digital integration corporations. Mr. Lyons has also served in various executive positions for several fortune 500 companies such as American Sterilizer Company, Everest and Jennings and Allscripts. Mr. Lyon's professional experience with start-up companies in the medical technology industry as well as his knowledge in finance provide the Company with guidance in capital formation and sustainability. He holds an MBA in finance and a BA in Philosophy.

Mr. Berman, officer and director, devotes his complete business time to the Company. Mr. Jagunich attends meetings of the board of directors when held and provides 33% of his business time in a professional capacity to the Company.

The following table sets forth information the remuneration of our Principal Executive officer for the years ended December 31, 2014 and 2013 and earned in excess of \$100,000 per annum during any part of our last two fiscal years:

#### Summary Compensation Table

Name and Principal Position	Year	Salary Bonus		Stock Awards	Option Awards	Non-Equity Incentive Plan Compensation	Nonqualified Deferred Compensation Earnings (\$)	All Other Compensation	Total (\$)
		(\$)	(\$)						
Keith Berman, CFO and PEO	2014	\$ -0-	\$ -0-	\$ -0-	-0-	-0-	-0-	-0-	\$314,204
	2013	\$ -0-	\$ -0-	\$ -0-	-0-	-0-	-0-	-0-	\$314,204

Mr. Berman has served as Chief Financial Officer since January 2003 and as Principal Executive Officer since August 2006. During the fiscal years ended December 31, 2014 and 2013 Mr. Berman has not received any form of compensation as a result of our limited cash flow; Mr. Berman has agreed to accept stock awards as his sole compensation until such time the Company has the necessary resources available to provide a traditional compensation plan.

Name of Beneficial Owner, Officer or Director	Number of Shares	Percent of Outstanding Shares of Common Stock <sup>(1)</sup>
Keith Berman, Chief Financial Officer and Director	480,103	3.5%
Robert Jagunich, Director	929,301	6.7%
William Lyons	-	-
Directors and Officers as a Group	1,409,404	10.2%
Barbara Asbell 7061 Los Coyotes Camarillo, CA 93012	1,162,590	8.3%
Directors, Officers and Beneficial Owners as a Group	2,571,994	18.5%

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

None

- C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

None

## **9) Third Party Providers**

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

### Legal Counsel

Name: Thomas C. Cook

Firm: Law Offices of Thomas C. Cook

Address 1: 8250 W. Charleston Blvd. Ste. 120

Address 2: Las Vegas, NV 89117

Phone: (702) 242-0099

Email: tcesq@aol.com

## **10) Issuer Certification**

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

## CERTIFICATION

I, Keith Berman, certify that;

(1) I have reviewed this disclosure statement and Annual Report years ended December 31, 2014 and December 31, 2013, of Decision Diagnostics Corp.

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) reevaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

(5) I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: April 15, 2015

/s/Keith Berman

Keith Berman

Principal Executive Officer and a Director

(Principal Financial Officer)

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER  
PURSUANT TO 18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

The undersigned, Keith Berman, the Principal Executive Officer of Decision Diagnostics Corp., and Principal Financial Officer of Decision Diagnostics Corp., hereby certifies, that, to his knowledge, the Annual Report of Decision Diagnostics Corp. for the fiscal years ended December 31, 2014 and December 31, 2013, fully complies with the requirements of this Disclosure Statement and of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Annual Report and this disclosure fairly presents in all material respects the financial condition and results of operations of Decision Diagnostics Corp.

Date: April 15, 2015

/s/Keith Berman

Keith Berman

Principal Executive Officer and  
Principal Financial Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signatures that appear in typed form within the electronic version of this written statement required by Section 906, has been provided to InstaCare Corp. and will be retained by InstaCare Corp. and furnished to the Securities and Exchange Commission or its staff upon request.